First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

European Journal of Cancer

Volumn 50, Issue 18, 2014, Pages 3178-3186

  Young, R J ^a   Natukunda, A ^b   Litiere S ^b   Woll, P J ^a   Wardelmann, E ^c   Van Der Graaf, W T A ^d  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b EORTC DATA CENTER   (Belgium)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiosarcoma; Chemotherapy; Doxorubicin; Soft tissue sarcoma

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; VINCRISTINE; ANTINEOPLASTIC ANTIBIOTIC;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; ADOLESCENT; HEMANGIOSARCOMA; KAPLAN MEIER METHOD; META ANALYSIS; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SARCOMA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HEMANGIOSARCOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOMA; YOUNG ADULT;

EID: 84925221841     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.10.004     Document Type: Article

References (37)

1. R.J. Young, N.J. Brown, M.W. Reed, D. Hughes, and P.J. Woll Angiosarcoma Lancet Oncol 11 10 2010 983 991
2. J.R. Toro, L.B. Travis, H.J. Wu, K. Zhu, C.D. Fletcher, and S.S. Devesa Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases Int J Cancer 119 12 2006 2922 2930
3. National Cancer Intelligence Network. Soft tissue sarcoma incidence and survival; tumours diagnosed in England between 1985 and 2009; 2012. < www.ncin.org.uk >.
4. S. Weiss, and J. Goldblum Malignant vascular tumours S. Weiss, J. Goldblum, Enzinger & Weiss's soft tissue tumours 4th ed. 2001 Mosby 917 937
5. A.L. Depla, C.H. Scharloo-Karels, M.A. de Jong, S. Oldenborg, M.W. Kolff, and S.B. Oei Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review Eur J Cancer 50 10 2014 1779 1788
6. G. Lahat, A.R. Dhuka, H. Hallevi, L. Xiao, C. Zou, and K.D. Smith Angiosarcoma: clinical and molecular insights Ann Surg 251 6 2010 1098 1106
7. R.G. Maki, D.R. D'Adamo, M.L. Keohan, M. Saulle, S.M. Schuetze, and S.D. Undevia Phase II study of sorafenib in patients with metastatic or recurrent sarcomas J Clin Oncol 27 19 2009 3133 3140
8. I. Ray-Coquard, A. Italiano, E. Bompas, A. Le Cesne, Y.M. Robin, and C. Chevreau Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO) Oncologist 17 2 2012 260 266
9. M. Agulnik, J.L. Yarber, S.H. Okuno, M. von Mehren, B.D. Jovanovic, and B.E. Brockstein An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas Ann Oncol 24 1 2013 257 263
10. M. Schlemmer, P. Reichardt, J. Verweij, J.T. Hartmann, I. Judson, and A. Thyss Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group Eur J Cancer 44 16 2008 2433 2436
11. N. Penel, B.N. Bui, J.O. Bay, D. Cupissol, I. Ray-Coquard, and S. Piperno-Neumann Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study J Clin Oncol 26 32 2008 5269 5274
12. The ESMO/European Sarcoma Network Working Group Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology 23 Suppl. 7 2012 vii92 vii99
13. H.M. Pinedo, V.H. Bramwell, H.T. Mouridsen, R. Somers, C.P. Vendrik, and A. Santoro Cyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group Cancer 53 9 1984 1825 1832
14. H.T. Mouridsen, L. Bastholt, R. Somers, A. Santoro, V. Bramwell, and J.H. Mulder Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer Clin Oncol 23 10 1987 1477 1483
15. J. Schütte, H.T. Mouridsen, W. Stewart, A. Santoro, A.T. van Oosterom, and R. Somers Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 26 5 1990 558 561
16. A. Santoro, T. Tursz, H. Mouridsen, J. Verweij, W. Steward, and R. Somers Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol 13 7 1995 1537 1545
17. W.P. Steward, J. Verweij, R. Somers, D. Spooner, P. Kerbrat, and M. Clavel Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group J Clin Oncol 11 1 1993 15 21
18. O.S. Nielsen, P. Dombernowsky, H. Mouridsen, D. Crowther, J. Verweij, and J. Buesa High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group Br J Cancer 78 12 1998 1634 1639
19. A. Le Cesne, I. Judson, D. Crowther, S. Rodenhuis, H.J. Keizer, and Q. Van Hoesel Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group J Clin Oncol 18 14 2000 2676 2684
20. J. Verweij, S.M. Lee, W. Ruka, J. Buesa, R. Coleman, and R. van Hoessel Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group J Clin Oncol 18 10 2000 2081 2086
21. I. Judson, J.A. Radford, M. Harris, J.Y. Blay, Q. van Hoesel, and A. le Cesne Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 37 7 2001 870 877
22. P. Lorigan, J. Verweij, Z. Papai, S. Rodenhuis, A. Le Cesne, and M.G. Leahy Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study J Clin Oncol 25 21 2007 3144 3150
23. I. Judson, J. Verweij, H. Gelderblom, J.T. Hartmann, P. Schöffski, and J.Y. Blay Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 4 2014 415 423
24. J.R. Kroep, M. Ouali, H. Gelderblom, A. Le Cesne, T.J. Dekker, and M. Van Glabbeke First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study Ann Oncol 22 1 2011 207 214
25. S. Sleijfer, M. Ouali, M. van Glabbeke, A. Krarup-Hansen, S. Rodenhuis, and A. Le Cesne Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) Eur J Cancer 46 1 2010 72 83
26. N. Penel, A. Italiano, I. Ray-Coquard, L. Chaigneau, C. Delcambre, and Y.M. Robin Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome Ann Oncol 23 2 2012 517 523
27. A. Italiano, A. Cioffi, N. Penel, M.G. Levra, C. Delcambre, and E. Kalbacher Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas Cancer 118 13 2012 3330 3336
28. N. Penel, J.-Y. Blay, O. Mir, E. Tresch, E. Bompas, and J. Domont ANGIOTAX-PLUS trial: a randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS) ASCO Meet Abstr 32 15 2014 10501
29. C.R. Antonescu, A. Yoshida, T. Guo, N.E. Chang, L. Zhang, and N.P. Agaram KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors Cancer Res 69 18 2009 7175 7179
30. J. Manner, B. Radlwimmer, P. Hohenberger, K. Mössinger, S. Küffer, and C. Sauer MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema Am J Pathol 176 1 2010 34 39
31. T. Guo, L. Zhang, N.E. Chang, S. Singer, R.G. Maki, and C.R. Antonescu Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions Genes Chromosomes Cancer 50 1 2011 25 33
32. T. Mentzel, H.U. Schildhaus, G. Palmedo, R. Büttner, and H. Kutzner Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases Mod Pathol 25 1 2012 75 85
33. S. Behjati, P.S. Tarpey, H. Sheldon, I. Martincorena, P. Van Loo, and G. Gundem Recurrent PTPRB and PLCG1 mutations in angiosarcoma Nat Genet 2014 [advance online publication]
34. W.T. van der Graaf, J.Y. Blay, S.P. Chawla, D.W. Kim, B. Bui-Nguyen, and P.G. Casali Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 379 9829 2012 1879 1886
35. M. Endo, and T.O. Nielsen Pazopanib for metastatic soft-tissue sarcoma Lancet 380 9844 2012 801 [author reply 801]
36. J. Montalvo, C. Spencer, A. Hackathorn, K. Masterjohn, A. Perkins, and C. Doty ROCK1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression Curr Mol Med 13 1 2013 205 219
37. R.J. Young, P.J. Woll, C.A. Staton, M.W. Reed, and N.J. Brown Vascular-targeted agents for the treatment of angiosarcoma Cancer Chemother Pharmacol 73 2 2014 259 270